Orogen Therapeutics is a drug discovery company utilizing proprietary, AI-enabled DNA encoded library (DEL) technology to identify novel chemical matter against medically and commercially attractive drug targets. Our mission is to deliver groundbreaking clinical solutions to patients with serious unmet medical needs.

The company is revolutionizing small-molecule drug discovery through its proprietary platform integrating DNA-encoded libraries (DEL) with massive chemical diversity of billions of compounds, virtual screening and AI-driven computation. The company's proprietary, one-of-a-kind target-specific FocusDEL™ (patent pending) seeks to innovate the DEL landscape by enabling enriched hit yields from immense chemical spaces. At present, our 140+ DNA-encoded libraries encompass over 40,000 building blocks and 16 billion screenable compounds.

Harnessing the power of this platform, we are exploring multiple target classes. Our primary emphasis is on cytokine targets involved in immuno-inflammatory disorders (INI). Early screening successes yielded hit series against multiple cytokine targets, with several candidates in lead optimization moving toward anticipated near-term lead selection.

Medically and commercially successful biologics developed for cytokine targets have validated the value of this space in multiple therapeutic areas including dermatology, rheumatology and gastroenterology for indications like psoriasis, eczema, psoriatic arthritis, rheumatoid arthritis, Crohn's disease and IBD. Oral small molecule medicines with good safety and efficacy profiles may represent attractive options for many patients.

Orogen's team includes scientists with decades of drug development experience and deep expertise in all aspects of small-molecule R&D, including DNA-encoded libraries, target selection and evaluation, cutting-edge AI and data science.